Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites-Reference-Cited by-同舟云学术

Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites

Published:2022-12-05 Issue: Volume: Page:
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Martin Alexandra L.,Powell Chase,Nagy Mate Z.,Innamarato Patrick,Powers John,Nichols Derek,Anadon Carmen M.,Chaurio Ricardo A.,Kim Sungjune,Wang Min-hsuan,Gong Bing,Wang Xianzhe,Scheutz Thomas J.,Antonia Scott J.,Conejo-Garcia Jose R.,Perez Bradford A.

Funder

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-022-03325-y.pdf

Reference68 articles.

1. Munhoz RR, Postow MA (2018) Clinical development of PD-1 in advanced melanoma. Cancer J 24(1):7–14. https://doi.org/10.1097/PPO.0000000000000299

2. Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, Wolchok JD (2015) Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol 1(4):433–440. https://doi.org/10.1001/jamaoncol.2015.1184

3. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. https://doi.org/10.1056/NEJMoa1003466